Literature DB >> 19085912

ATP13A2 variability in Parkinson disease.

Carles Vilariño-Güell1, Alexandra I Soto, Sarah J Lincoln, Samia Ben Yahmed, Mounir Kefi, Michael G Heckman, Mary M Hulihan, Hua Chai, Nancy N Diehl, Rim Amouri, Alex Rajput, Deborah C Mash, Dennis W Dickson, Lefkos T Middleton, Rachel A Gibson, Faycal Hentati, Matthew J Farrer.   

Abstract

Recessively inherited mutations in ATP13A2 result in Kufor-Rakeb syndrome (KRS), whereas genetic variability and elevated ATP13A2 expression have been implicated in Parkinson disease (PD). Given this background, ATP13A2 was comprehensively assessed to support or refute its contribution to PD. Sequencing of ATP13A2 exons and intron-exon boundaries was performed in 89 probands with familial parkinsonism from Tunisia. The segregation of mutations with parkinsonism was subsequently assessed within pedigrees. The frequency of genetic variants and evidence for association was also examined in 240 patients with nonfamilial PD and 372 healthy controls. ATP13A2 mRNA expression was also quantified in brain tissues from 38 patients with nonfamilial PD and 38 healthy subjects from the United States. Sequencing analysis revealed 37 new variants; seven missense, six silent, and 24 that were noncoding. However, no single ATP13A2 mutation segregated with familial parkinsonism in either a dominant or recessive manner. Four markers showed marginal association with nonfamilial PD, prior to correction for multiple testing. ATP13A2 mRNA expression was marginally decreased in PD brains compared with tissue from control subjects. In conclusion, neither ATP13A2 genetic variability nor quantitative gene expression in brain appears to contribute to familial parkinsonism or nonfamilial PD. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19085912      PMCID: PMC2650009          DOI: 10.1002/humu.20877

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation.

Authors:  Andrew J Lees; Andrew B Singleton
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

3.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.

Authors:  A J Hughes; Y Ben-Shlomo; S E Daniel; A J Lees
Journal:  Neurology       Date:  1992-06       Impact factor: 9.910

6.  Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome.

Authors:  A S Najim al-Din; A Wriekat; A Mubaidin; M Dasouki; M Hiari
Journal:  Acta Neurol Scand       Date:  1994-05       Impact factor: 3.209

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study.

Authors:  Neziha Gouider-Khouja; Abdelmajid Larnaout; Rim Amouri; Sana Sfar; Samir Belal; Christiane Ben Hamida; Mongi Ben Hamida; Nobutaka Hattori; Yoshikuni Mizuno; Fayçal Hentati
Journal:  Parkinsonism Relat Disord       Date:  2003-06       Impact factor: 4.891

9.  PINK1 mutations and parkinsonism.

Authors:  L Ishihara-Paul; M M Hulihan; J Kachergus; R Upmanyu; L Warren; R Amouri; R Elango; R K Prinjha; A Soto; M Kefi; M Zouari; S B Sassi; S B Yahmed; G El Euch-Fayeche; P M Matthews; L T Middleton; R A Gibson; F Hentati; M J Farrer
Journal:  Neurology       Date:  2008-08-06       Impact factor: 9.910

10.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.

Authors:  A Di Fonzo; H F Chien; M Socal; S Giraudo; C Tassorelli; G Iliceto; G Fabbrini; R Marconi; E Fincati; G Abbruzzese; P Marini; F Squitieri; M W Horstink; P Montagna; A Dalla Libera; F Stocchi; S Goldwurm; J J Ferreira; G Meco; E Martignoni; L Lopiano; L B Jardim; B A Oostra; E R Barbosa; V Bonifati
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

View more
  12 in total

1.  ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese.

Authors:  Gerda Rentschler; Loredana Covolo; Amelia Ahmadi Haddad; Roberto G Lucchini; Silvia Zoni; Karin Broberg
Journal:  Neurotoxicology       Date:  2012-01-20       Impact factor: 4.294

2.  Atp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease.

Authors:  Cynthia A Kelm-Nelson; Sharon A Stevenson; Michelle R Ciucci
Journal:  Neurosci Lett       Date:  2016-04-04       Impact factor: 3.046

3.  The impact of genetic research on our understanding of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.

Authors:  Jason P Covy; Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2012-07-30       Impact factor: 4.164

5.  The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease.

Authors:  Anne Y Y Chan; Larry Baum; Nelson L S Tang; Christine Y K Lau; Ping Wing Ng; Kwok Fai Hui; Yoshi Mizuno; Justin Y Kwan; Vincent C T Mok; Sheng-Han Kuo
Journal:  J Clin Neurosci       Date:  2013-03-20       Impact factor: 1.961

6.  Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts.

Authors:  Michael C Kruer; Reema Paudel; Wendy Wagoner; Lynn Sanford; Eleanna Kara; Allison Gregory; Tom Foltynie; Andrew Lees; Kailash Bhatia; John Hardy; Susan J Hayflick; Henry Houlden
Journal:  Neurosci Lett       Date:  2012-06-25       Impact factor: 3.046

7.  Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.

Authors:  Jose Bras; Alain Verloes; Susanne A Schneider; Sara E Mole; Rita J Guerreiro
Journal:  Hum Mol Genet       Date:  2012-03-02       Impact factor: 6.150

Review 8.  Splicing: is there an alternative contribution to Parkinson's disease?

Authors:  Valentina La Cognata; Velia D'Agata; Francesca Cavalcanti; Sebastiano Cavallaro
Journal:  Neurogenetics       Date:  2015-05-16       Impact factor: 2.660

Review 9.  Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach.

Authors:  Valentina La Cognata; Giovanna Morello; Velia D'Agata; Sebastiano Cavallaro
Journal:  Hum Genet       Date:  2016-11-28       Impact factor: 4.132

Review 10.  Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.

Authors:  Xinglong Yang; Yanming Xu
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.